January 1, 2006Thrombosis and Haemostasis

Selective COX-2 inhibitors and risk of thromboembolic events – regulatory aspects

View Full Paper

Ask AI

Bookmark

Why the study?

What are the regulatory actions taken regarding the cardiovascular safety of selective COX-2 inhibitors?

Population

Patients using selective COX-2 inhibitors (coxibs)

Design

Review

Authors

KBKarl BroichFederal Institute for Drugs and Medical Devices HHHans‐Karl HeimFederal Institute for Drugs and Medical Devices

Discussion

Member takes

Implication

Warrants review of NSAID choices in vascular disease patients; leaves open comparative safety of non-selective agents.

Structured PICO

What are the regulatory actions taken regarding the cardiovascular safety of selective COX-2 inhibitors?

Population

Patients using selective COX-2 inhibitors (coxibs)

Intervention

Selective COX-2 inhibitors (coxibs) including rofecoxib, celecoxib, etoricoxib, parecoxib/valdecoxib, and lumiracoxib

Outcome

Cardiovascular safety (thromboembolic events)safety

Regulatory review highlights the contraindication of COX-2 inhibitors in patients with established cardiovascular disease due to increased thromboembolic risk.

Cite This Study

Broich et al. (2006) studied this question.

synapsesocial.com/papers/6a782d58d8eb58afc2be6493 https://doi.org/10.1160/th06-08-0462

View Full Paper

Ask AI

Bookmark

Selective COX-2 inhibitors and risk of thromboembolic events – regulatory aspects

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Selective COX-2 inhibitors and risk of thromboembolic events – regulatory aspects

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider